表紙
市場調查報告書

醫藥品連續生產的全球市場的預測

Global Pharmaceutical Continuous Manufacturing Market Forecast 2020-2028

出版商 Inkwood Research 商品編碼 931963
出版日期 內容資訊 英文 168 Pages
商品交期: 2-3個工作天內
價格
醫藥品連續生產的全球市場的預測 Global Pharmaceutical Continuous Manufacturing Market Forecast 2020-2028
出版日期: 2020年04月13日內容資訊: 英文 168 Pages
簡介

全球醫藥品連續生產市場在2020年∼2028年間,預測將以8.45%的年複合成長率成長。持續藥物生產系統的普及,及新興國家的未開發市場成長性,政府及FDA擴大推動普及的舉措,勝過傳統醫藥品生產系統的優點等正在推動這個市場的增長。。

本報告提供全球醫藥品連續生產市場調查,提供市場概要,各產品·用途·終端用戶·各地區的市場規模的變化與預測,市場成長要素及阻礙因素分析,市場機會,競爭情形,主要企業的簡介等全面性資訊。

目錄

第1章 調查範圍和調查手法

  • 調查目的
  • 調查範圍
  • 調查手法
  • 前提與限制

第2章 摘要整理

  • 市場規模與預測
  • 市場概要

第3章 市場動態

  • 市場定義
  • 成長要素
    • 未開發的新興市場上開發機會
    • 製藥連續製造系統的採用增加
    • 政府擴大採用連續製造系統的配合措施
  • 阻礙因素
    • 客戶的期待增加
    • 開發中國家缺乏連續製造系統的需求

第4章 市場分析

  • 波特的五力分析
    • 買方議價能力
    • 供給企業談判力
    • 新加入廠商業者的威脅
    • 替代品的威脅
    • 競爭企業間的敵對關係
  • 法律規範
  • 機遇矩陣
  • 業者情勢
  • 投資洞察

第5章 全球醫藥品連續生產市場:各產品

  • 整合連續系統
  • 半連續系統
  • 控制軟體

第6章 全球醫藥品連續生產市場:各用途

  • 最終產品製造
  • API(醫藥品原料藥)製造

第7章 全球醫藥品連續生產市場:各終端用戶

  • 製藥企業
  • CMO(醫藥品受託製造廠商)
  • 其他

第8章 全球醫藥品連續生產市場:各地區

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 比利時
    • 波蘭
    • 其他
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲·紐西蘭
    • 韓國
    • 泰國
    • 印尼
    • 越南
    • 其他
  • 其他地區
    • 南美
    • 中東·非洲

第9章 企業簡介

  • COPERION GMBH
  • ELI LILLY & COMPANY
  • GEA GROUP AG
  • GEBRUDER LODIGE MASCHINENBAU GMBH
  • GLATT GMBH
  • hosokawamikuron
  • KORSCH AG
  • L.B. BOHLE MASCHINEN + VERFAHREN GMBH
  • MUNSON MACHINERY COMPANY
  • PFIZER INC
  • SIEMENS HEALTHINEERS
  • SYNTEGON
  • THERMO FISHER SCIENTIFIC INC
目錄
Product Code: 30916

KEY FINDINGS:

The global pharmaceutical continuous marketing market is anticipated to register a CAGR of 8.45% over the forecast period of 2020-2028. The factors contributing to the growth of the market are the rising adoption of pharmaceutical continuous marketing systems, growth opportunities in unexplored emerging economies, and increasing government initiatives for the adoption of pharmaceutical continuous marketing systems. Further, initiatives taken by the FDA for promoting the use of pharmaceutical CM systems and their advantage over the existing drug manufacturing process are the other crucial factors fueling the market growth.

MARKET INSIGHTS:

Continuous manufacturing is a developed manufacturing process to prepare pharmaceutical products in a short span of time with improved quality, enhanced yield, and lower cost of production. The opportunities offered by the emerging untapped markets are an enhanced pharmaceutical infrastructure, a growing number of pharmaceutical industries, and a surge in demand for pharmaceutical CM systems. The market is categorized into an integrated continuous system, semi-continuous system, and control & software depending on the product. The integrated continuous system dominates the global market in terms of revenue and market share. It is attributed to low cost, time efficiency, high quality of the product productivity, and no manual. However, the higher cost of pharmaceutical manufacturing systems continuous systems hinders the market growth. The intensity of competition in the market is moderate to high, owing to the high growth of the market but low product differentiation.

REGIONAL INSIGHTS:

The global pharmaceutical continuous marketing market is geographically segmented into North America, Europe, Asia Pacific, and the Rest of the World. As of 2019, the region of North America dominated the market in terms of revenue, and is projected to maintain the trend until the end of the forecast period. This is attributed to major factors such as the presence of well-developed infrastructure in pharmaceutical industries, together with a rise in the use of continuous manufacturing systems, among various other factors.

COMPETITIVE INSIGHTS:

There are many prominent players functioning and registering their presence in the global market, such as Eli Lilly and Company, Hosokawa Micron Corporation, GEA Group, L.B. Bohle Glatt GmbH, etc.

Our report offerings include:

  • Explore key findings of the overall market
  • Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
  • Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
  • Market Segmentation cater to a thorough assessment of key segments with their market estimations
  • Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
  • Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
  • Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
  • Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

TABLE OF CONTENTS

1. RESEARCH SCOPE & METHODOLOGY

  • 1.1. STUDY OBJECTIVES
  • 1.2. SCOPE OF STUDY
  • 1.3. METHODOLOGY
  • 1.4. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY

  • 2.1. MARKET SIZE & ESTIMATES
  • 2.2. MARKET OVERVIEW

3. MARKET DYNAMICS

  • 3.1. MARKET DEFINITION
  • 3.2. KEY DRIVERS
    • 3.2.1. DEVELOPMENT OPPORTUNITIES IN UNTAPPED EMERGING MARKETS
    • 3.2.2. INCREASED ADOPTION OF PHARMACEUTICAL CONTINUOUS MANUFACTURING SYSTEMS
    • 3.2.3. RISING GOVERNMENT INITIATIVES FOR THE ADOPTION OF CONTINUOUS MANUFACTURING SYSTEMS
  • 3.3. KEY RESTRAINTS
    • 3.3.1. INCREASING CUSTOMER ANTICIPATIONS
    • 3.3.2. LACK OF DEMAND FOR THE CONTINUOUS MANUFACTURING SYSTEMS IN UNDERDEVELOPED COUNTRIES

4. KEY ANALYTICS

  • 4.1. PORTER'S FIVE FORCE ANALYSIS
    • 4.1.1. THREAT OF NEW ENTRY
    • 4.1.2. THREAT OF SUBSTITUTION
    • 4.1.3. BUYER'S POWER
    • 4.1.4. SUPPLIER'S POWER
    • 4.1.5. COMPETITIVE RIVALRY
  • 4.2. REGULATORY FRAMEWORK
  • 4.3. OPPORTUNITY MATRIX
  • 4.4. VENDOR LANDSCAPE
  • 4.5. KEY INVESTMENT INSIGHTS

5. MARKET BY PRODUCT

  • 5.1. INTEGRATED CONTINUOUS SYSTEM
  • 5.2. SEMI-CONTINUOUS SYSTEM
  • 5.3. CONTROL & SOFTWARE

6. MARKET BY APPLICATION

  • 6.1. FINAL DRUG PRODUCT MANUFACTURING
  • 6.2. API MANUFACTURING

7. MARKET BY END-USER

  • 7.1. PHARMACEUTICAL COMPANIES
  • 7.2. CONTRACT MANUFACTURING ORGANIZATIONS
  • 7.3. OTHER END-USERS

8. GEOGRAPHICAL ANALYSIS

  • 8.1. NORTH AMERICA
    • 8.1.1. THE UNITED STATES
    • 8.1.2. CANADA
  • 8.2. EUROPE
    • 8.2.1. THE UNITED KINGDOM
    • 8.2.2. FRANCE
    • 8.2.3. GERMANY
    • 8.2.4. ITALY
    • 8.2.5. RUSSIA
    • 8.2.6. BELGIUM
    • 8.2.7. POLAND
    • 8.2.8. REST OF EUROPE
  • 8.3. ASIA PACIFIC
    • 8.3.1. CHINA
    • 8.3.2. JAPAN
    • 8.3.3. INDIA
    • 8.3.4. AUSTRALIA & NEW ZEALAND
    • 8.3.5. SOUTH KOREA
    • 8.3.6. THAILAND
    • 8.3.7. INDONESIA
    • 8.3.8. VIETNAM
    • 8.3.9. REST OF ASIA PACIFIC
  • 8.4. REST OF WORLD
    • 8.4.1. LATIN AMERICA
    • 8.4.2. MIDDLE EAST & AFRICA

9. COMPANY PROFILES

  • 9.1. COPERION GMBH
  • 9.2. ELI LILLY & COMPANY
  • 9.3. GEA GROUP AG
  • 9.4. GEBRUDER LODIGE MASCHINENBAU GMBH
  • 9.5. GLATT GMBH
  • 9.6. HOSOKAWA MICRON CORPORATION
  • 9.7. KORSCH AG
  • 9.8. L.B. BOHLE MASCHINEN + VERFAHREN GMBH
  • 9.9. MUNSON MACHINERY COMPANY
  • 9.10. PFIZER INC
  • 9.11. SIEMENS HEALTHINEERS
  • 9.12. SYNTEGON (FORMERLY BOSCH PACKAGING TECHNOLOGY)
  • 9.13. THERMO FISHER SCIENTIFIC INC

LIST OF TABLES

  • TABLE 1: MARKET SNAPSHOT - PHARMACEUTICAL CONTINUOUS MANUFACTURING
  • TABLE 2: GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY PRODUCT, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 3: GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY PRODUCT, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 4: GLOBAL INTEGRATED CONTINUOUS SYSTEM MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 5: GLOBAL INTEGRATED CONTINUOUS SYSTEM MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 6: GLOBAL SEMI-CONTINUOUS SYSTEM MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 7: GLOBAL SEMI-CONTINUOUS SYSTEM MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 8: GLOBAL CONTROL & SOFTWARE MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 9: GLOBAL CONTROL & SOFTWARE MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 10: GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY APPLICATION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 11: GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY APPLICATION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 12: GLOBAL FINAL DRUG PRODUCT MANUFACTURING MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 13: GLOBAL FINAL DRUG PRODUCT MANUFACTURING MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 14: GLOBAL API MANUFACTURING MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 15: GLOBAL API MANUFACTURING MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 16: GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY END-USER, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 17: GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY END-USER, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 18: GLOBAL PHARMACEUTICAL COMPANIES MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 19: GLOBAL PHARMACEUTICAL COMPANIES MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 20: GLOBAL CONTRACT MANUFACTURING ORGANIZATIONS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 21: GLOBAL CONTRACT MANUFACTURING ORGANIZATIONS MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 22: GLOBAL OTHER END-USERS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 23: GLOBAL OTHER END-USERS MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 24: GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 25: GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 26: NORTH AMERICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 27: NORTH AMERICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 28: EUROPE PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 29: EUROPE PHARMACEUTICAL CONTINUOUS MANUFACTURING, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 30: ASIA PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 31: ASIA PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 32: REST OF WORLD PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 33: REST OF WORLD PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

LIST OF FIGURES

  • FIGURE 1: PORTER'S FIVE FORCE ANALYSIS
  • FIGURE 2: OPPORTUNITY MATRIX
  • FIGURE 3: VENDOR LANDSCAPE
  • FIGURE 4: KEY INVESTMENT INSIGHTS
  • FIGURE 5: GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY PRODUCT, IN 2019
  • FIGURE 6: GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY INTEGRATED CONTINUOUS SYSTEM, 2020-2028 (IN $ MILLION)
  • FIGURE 7: GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY SEMI-CONTINUOUS SYSTEM, 2020-2028 (IN $ MILLION)
  • FIGURE 8: GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY CONTROL & SOFTWARE, 2020-2028 (IN $ MILLION)
  • FIGURE 9: GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY APPLICATION, IN 2019
  • FIGURE 10: GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY FINAL DRUG PRODUCT MANUFACTURING, 2020-2028 (IN $ MILLION)
  • FIGURE 11: GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY API MANUFACTURING, 2020-2028 (IN $ MILLION)
  • FIGURE 12: GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY END-USER, IN 2019
  • FIGURE 13: GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY PHARMACEUTICAL COMPANIES, 2020-2028 (IN $ MILLION)
  • FIGURE 14: GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY CONTRACT MANUFACTURING ORGANIZATIONS, 2020-2028 (IN $ MILLION)
  • FIGURE 15: GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY OTHER END-USERS, 2020-2028 (IN $ MILLION)
  • FIGURE 16: NORTH AMERICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, COUNTRY OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 17: THE UNITED STATES PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 18: CANADA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 19: EUROPE PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, COUNTRY OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 20: THE UNITED KINGDOM PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 21: FRANCE PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 22: GERMANY PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 23: ITALY PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 24: RUSSIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 25: BELGIUM PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 26: POLAND PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 27: REST OF EUROPE PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 28: ASIA PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, COUNTRY OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 29: CHINA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 30: JAPAN PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 31: INDIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 32: AUSTRALIA & NEW ZEALAND PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 33: SOUTH KOREA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 34: THAILAND PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 35: INDONESIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 36: VIETNAM PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 37: REST OF ASIA PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 38: REST OF WORLD PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, REGIONAL OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 39: LATIN AMERICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 40: MIDDLE EAST & AFRICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2020-2028 (IN $ MILLION)